Allied Market Research added new research on U.S. AntiCoagulants Market Opportunity Analysis and Industry Forecast,2023-2032.
Intoduction Of U.S. U.S. AntiCoagulants Market
Anticoagulants are used to treat blood clotting. Blood clots are formed when platelets aggregate and protein binds to form a solid mass. However, blood clotting is essential to stop excessive bleeding in diseases such as hemophilia. Anticoagulants are used to treat clot formation by stopping the platelets aggregation.
The major factors that contribute to the growth of the U.S. Anticoagulants market include increase in prevalence of hematic diseases such as hemophilia, thalassemia, and others and rise in geriatric population.
Moreover, large number of clinical trials and innovative R&D approaches to develop advanced drugs drive the market growth. However, side effects such as, nose bleeding, bleeding gums and respiratory discomfort, and stringent regulation hinder the market. Increase in R&D activities in the field of pharmaceutical industries and rise in therapeutical applications are anticipated to provide new opportunities for the market.
Request Sample Copy of Report: https://www.alliedmarketresearch.com/request-toc-and-sample/3983
Direct Oral Anticoagulants (DOACs):
DOACs, such as apixaban, rivaroxaban, edoxaban, and dabigatran, have gained popularity as alternatives to traditional anticoagulants like warfarin. Their convenience, reduced need for monitoring, and comparable or improved efficacy and safety profiles have contributed to their increased adoption.
Expanding Indications:
Anticoagulants are used in various conditions, including atrial fibrillation, deep vein thrombosis, pulmonary embolism, and stroke prevention. Market growth has been influenced by the expanding indications for anticoagulant therapies.
Reversal Agents:
The development and approval of reversal agents for certain anticoagulants, particularly for DOACs, have addressed concerns about bleeding complications. Reversal agents like idarucizumab for dabigatran and andexanet alfa for factor Xa inhibitors provide physicians with tools to manage anticoagulant-related bleeding.
Key Benefits For Stakeholders:
- The study provides an in-depth analysis of the U.S. Anticoagulants market with current trends and future estimations to elucidate the investment pockets.
- Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
- The report offers a quantitative analysis to assist the stakeholders to capitalize on prevailing market opportunities.
- Extensive analysis of different segments facilitates to determine various products available in the market.
- Key players are profiled and their strategies are analyzed thoroughly to predict the competitive market outlook.
List of players profiled in the report
- Alere,
- Daiichi Sankyo,
- Abbott,
- Roche,
- CoaguSense,
- Bristol-Myers Squibb,
- C. H. Boehringer Sohn,
- Pfizer,
- Johnson & Johnson,
- Portola Pharmaceuticals
For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/3983
About Us
Allied Market Research is market research, consulting, and advisory firm of Allied Analytics LLP. Founded in 2013, the firm has been instrumental in offering high-quality syndicated and customized market research reports, consulting services, and useful insights to leading market players, startups, investors, and stakeholders. Driven by the aim to eliminate sub-standard data and become a successful partner for organizations, Allied Market Research has been innovating continuously, expanding the product & service portfolio, and implementing the client-first approach since its inception. With the clientele spanning more than 7,000 organizations that also include a majority of Fortune 500 companies, AMR has a proven track record of helping and serving the global clientele and playing a major role in their success.
Contact
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
